Quarterly ResultAug 5, 2026, 05:28 PM
ADMA Biologics Q2 Net Income Up 10.5%; H1 EPS Up 40%
AI Summary
ADMA Biologics reported a 10.5% increase in Q2 net income to $37.8 million and a 40% rise in H1 diluted EPS to $0.35. The company saw a substantial improvement in net cash provided by operating activities, reaching $87.8 million for the first half of 2026. This period also included a significant acquisition of treasury stock totaling $155.2 million and an increase in long-term debt.
Key Highlights
- Q2 2026 Net Income increased 10.5% to $37.8 million.
- H1 2026 Diluted EPS rose 40% to $0.35.
- Q2 2026 Revenues grew 1.98% to $124.4 million.
- H1 2026 Net cash provided by operating activities was $87.8 million.
- Acquired $155.2 million in treasury stock during H1 2026.
- Long-term debt increased to $192.8 million from $69.3 million.
- Cash and cash equivalents increased to $136.0 million.
Price Impact
More from ADMA
Quarterly ResultAug 5, 4:21 PM
ADMA Biologics Q2 Revenue $124.4M, Net Income $37.8M; Reiterates FY26 Guidance
Quarterly ResultMay 6, 5:22 PM
ADMA Biologics Q1 Net Income $45.3M, EPS $0.19; $130.2M Buyback
Quarterly ResultMay 6, 4:18 PM
ADMA Biologics Q1 Revenue $114.5M; Adj. Net Income +22%; Updates FY26 Outlook